Health Condition 1: N29- Other disorders of kidney and ureter in diseases classified elsewhere
Conditions
Interventions
Intervention1: Therapeutic plasma exchange by Centrifugal Technology: Therapeutic plasma exchange done by Centrifugal technology, patients allocated randomly in this arm total 10 cases to be allocated
Sponsors
PGIMER
Eligibility
Inclusion criteria
Inclusion criteria: 1.No evidence of active infection 2.Willing to give informed consent for the procedure (In patients who are incompetent to consent, consent shall be taken from the surrogate) 3.Those who not enrolled in any other study
Exclusion criteria
Exclusion criteria: 1.Pregnancy 2.Microbiological or radiological evidence of active infection 3.Known allergy to Plasma, Protamine or Heparin. 4.Severe systemic illness like HIV 5.Patients with vasculitis due to secondary causes (diagnosis of a different rheumatic disease, Hepatitis B, Hepatitis C, HIV infection) 6.Mechanically ventilated patients 7.Renal or any other transplant recepients would be excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| a.Compare the centrifugal and membrane filtration technologies for TPE in renal disease patients in terms of their efficacy in plasma removal. b.Compare the Post exchange clinical, biochemical, and hematological profile in the two groups c.Calculation of the TPE procedure costs in the two modalities Timepoint: recruitment 12 months results and analysis 2months | — |
Secondary
| Measure | Time frame |
|---|---|
| Patient Outcome- Adverse events and Morbidity and mortality at 30 days and 90 days TPE cycle completionTimepoint: at 30 and 90 days post TPE cycle completion | — |
Countries
India
Contacts
Public ContactDr Divjot Singh Lamba
PGIMER, Chandigarh.
Outcome results
None listed